AGIOS PHARMACEUTICALS, INC. (AGIO)

Agios Pharmaceuticals emerged from foundational cellular metabolism research at major academic institutions. The company was founded in 2008 by cancer researchers Lewis Cantley, Tak Mak, and Craig Thompson, who set out to discover small-molecule drugs that could modulate metabolic pathways underlying disease. That orientation—starting from enzyme biology rather than clinical observation—shaped everything the company would become.

The company went public in 2013 and for its first decade pursued a dual strategy across both oncology and metabolic diseases. A 2016 partnership with Celgene signaled serious ambition in metabolic immuno-oncology. But the cancer franchise struggled clinically and financially, and in 2021 management made a defining choice: sell the entire oncology business to Servier for $1.8 billion and concentrate entirely on hemolytic anemias. It was a bold wager on a small patient population—pyruvate kinase deficiency affects perhaps 1,000 to 3,000 people in the U.S.—but one where almost no treatments existed.

Mitapivat (PYRUKYND) became the first FDA-approved medicine for adults with pyruvate kinase deficiency in 2022. The drug works by activating defective pyruvate kinase enzymes, restoring the cells’ metabolic machinery and allowing red blood cells to survive longer in the bloodstream. The clinical results were genuine: durable improvements in hemoglobin levels and transfusion independence in a population for which transfusions had been the only option. FDA approval moved rapidly, signaling how starved the market was for this therapy.

Agios now operates as a focused commercial-stage biotech. PYRUKYND generates meaningful revenue from a narrow but dedicated patient population. A companion drug, AQVESME (fabhalta), treats thalassemia patients. Pipeline expansion into sickle cell disease and pediatric applications represents the primary growth vector—larger populations addressing the same enzymatic pathway. The company maintains roughly 540 employees and operates from Cambridge, Massachusetts. It transformed from a cash-hungry oncology incubator into a rare-disease biotech with a clear product portfolio and a path to sustained profitability—demonstrating how deep science can find its market through strategic focus and a willingness to abandon the original thesis.

Related: 10-K, Public Company, Stock